Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

Mar 18, 2025 - 16:43
 0
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.